Introduction
============

Multiple co-existing mechanisms of neurological injury after cardiac operations have been described, especially in elderly patients with impaired vasomotor function or severe cerebrovascular disease. These include microembolization and macroembolization of the atheromatous plaque, air or clot from the aorta or from the cardiopulmonary bypass (CPB) circuit, and hypoperfusion of the brain when on CPB, not to forget hypoperfusion associated with the systemic inflammatory response.[@b1-cia-13-1837] Risk and prevention of air embolism associated with the CPB appears to be a real problem known almost from the beginning of cardiac surgery.[@b2-cia-13-1837],[@b3-cia-13-1837]

To evacuate air from the heart after open heart surgery, standard surgical maneuvers are used including filling and venting of the left ventricle, heart and lungs' ballottement, mechanical ventilation, placing the patient in Trendelenburg position, and needle aspiration. Despite these efforts, a significant amount of air remains. Flooding the surgical field with carbon dioxide (CO~2~) reduces the incidence of intracardiac air by approximately 85% due to the difference in CO~2~ density (1.5 times that of air) and solubility (360 times more soluble than air), which leads to the preferential filling of the dependent areas of surgical field with CO~2~ and a reduction in size of microemboli.[@b4-cia-13-1837],[@b5-cia-13-1837] Transesophageal echocardiography (TEE) shows that, when CO~2~ is used, the intracardiac air disappears rapidly (within minutes).[@b4-cia-13-1837] Obviously, the use of CO~2~ atmosphere may cause an increase in the partial pressure of CO~2~ and a decrease in the pH and base excess (BE).

Massive air embolism occurring due to a medical error of the perfusionist or the surgeon is extremely rare, but micro-embolism during open heart surgery despite using de-airing procedures is a common situation. Results of the former can be observed as stroke or death of the patient immediately during or after the operation. The latter is difficult to observe because the lesions, if they occur, are very small and may appear days, weeks, or even months later, for example, postoperative delirium, changes in personality, neurocognitive dysfunction, and intensification of dementia. However, it is possible that these changes are connected not with the operation itself but only with the status of the patient, their age, sex, severity of the disease, or genetic factors.[@b6-cia-13-1837]

The use of CO~2~ atmosphere during cardiac surgery has become standard practice in many cardiac surgery departments. CO~2~ is a natural gas, 25 times more soluble in blood than air. This means that bubbles of CO~2~ dissolve in blood more quickly than air bubbles.[@b7-cia-13-1837]--[@b9-cia-13-1837] It can be hypothesized that the shorter the time during which the gaseous micro-emboli dissolve and the fewer their number, the smaller the postoperative brain injury. So far, psychological tests and ultrasound examination were used to assess the size and impact of microemboli on the brain. However, there is very little direct evidence to demonstrate any real benefit of this practice. In order to determine the impact of the microemboli release on the brain, we used S100ß protein considered to be a specific marker of brain damage. Recently, this method was used by other authors in the evaluation of neurological changes after coronary artery by-pass grafting (CABG).[@b10-cia-13-1837],[@b11-cia-13-1837]

The S100 proteins are a family of small, dimeric multi-genic calcium-binding proteins comprising various combinations of A1 and B subunits, with a molecular weight of 10--12 kDa and a biological half-life of approximately 2 hours, first isolated from central nervous tissue in 1965. In the biologically active form, called S-100A1-A1, this protein is predominantly found in the heart, kidney, and striated muscles, as S-100A1-B in glial cells, melanocytes, adipocytes, chondrocytes, and epidermal Langerhans cells and S-100BB in astrocytes and Schwann cells.[@b12-cia-13-1837],[@b13-cia-13-1837]

The neuronal destruction and destabilization of the blood--brain barrier are accompanied by a release of S100ß protein into the blood. The S100ß is measurable within minutes after event and can be detected for an extended period in the blood. The S100ß is removed from the serum by the renal clearance pathway, with a half-life of 20--25 minutes. S100ß protein level is a sensitive and specific marker for brain injury after stroke, head trauma, and brain damage caused by circulatory arrest or cardiac surgery with CPB.[@b14-cia-13-1837]--[@b17-cia-13-1837] The role of serial measurement of serum S100ß protein has already been described. The protein has been proven to be a good marker of brain damage during CPB.[@b18-cia-13-1837]

Aim
===

The aim of our study was to measure the level of S100ß in blood plasma to assess the influence of CO~2~ field flooding on microembolism-induced brain damage.

Materials and methods
=====================

To enable this research, we obtained a grant from the Ministry of Science and Higher Education in Poland (NN403289536). An approval was obtained from the ethics committee of the Pomeranian Medical University in Szczecin, Poland (BN-001/6/08). The study was performed according to the Declaration of Helsinki. All patients received detailed written information about the background, aim, and methods of the study, and only those who signed an informed consent form were included in the study.

Study group
-----------

The study group consisted of adult patients scheduled for a planned mitral valve operation through median sternotomy with the use of CPB. We screened all patients between March 2008 and February 2011 and included 100 consecutive patients. The inclusion criteria were as follows: 1) age above 18 years, 2) mitral valve operation, 3) ability to understand Polish language, 4) ability to sign an informed consent, 5) no previous dementia, and 6) no history of psychiatric disorder. There were 357 patients undergoing mitral annuloplasty or replacement. The exclusion criteria were as follows: 1) patient refusal (68 cases), 2) reoperation (29 cases), 3) history of stroke (23 cases), 4) active endocarditis (16 cases), 5) concomitant aortic valve or aortic arch procedure (90 cases), and 6) mini-invasive mitral valve operation through right thoracotomy (30 cases). A concomitant procedure of tricuspid valve annuloplasty (TVA), or CABG performed as required, was not an exclusion criterion. Patients qualified for the operation of the mitral valve through median sternotomy were randomized into the following two groups: treatment group and control group.

Technical procedure description
-------------------------------

In all cases, a routine intraoperative TEE was performed prior to and after the CPB. Standard CPB technique with membrane oxygenator, nonpulsatile flow, two venous cannulas, and mean arterial pressure control was used. Patients were normothermic with continuous blood heating at 36.6°C. All patients underwent general anesthesia with endotracheal intubation according to a local protocol, with the use of etomidate and fentanyl at induction, muscle relaxation with pancuronium, and maintenance of anesthesia with sevoflurane and fentanyl. The standard cold crystalloid intermittent cardioplegic solution type St Thomas II was used. The de-airing procedures after restarting the heart were conducted with vent suction from the left atrium and ascending aorta under the control of TEE. Effort was undertaken to check for any residual air during the de-airing procedures, and the de-airing time was precisely planned to ensure cessation of any additional air bubbles from the pulmonary veins. All operations were performed by the same surgeon. Chest tubes were removed on postoperative day 1 or 2.

CO~2~ insufflation devices
--------------------------

For CO~2~ insufflation, a standard Redon drain was used consisting of a flexible PVC tube with an inner diameter of 2.5 mm and perforated at 10.0 cm toward the end part. Distal lumen was occluded with a typical Luer stopper. The perforated part of the drain tube was fixed with two sutures to the left side of the pericardium just below the left branch of the retractor and covered with gauze. The flow of CO~2~ was measured with a standard flowmeter for medical CO~2~. The flow of CO~2~ at 6 L/minute started 1 minute before opening the left atrium and ended after its closure. An increase in the partial pressure of CO~2~, consequent decrease in the pH and BE, was corrected by the perfusionist with a minimal increase in the volume of air added to the gas exchanger.

S100ß protein measurements
--------------------------

To analyze the changes in S100ß protein level, blood was collected at three points during the operation. The first 10 mL of blood sample (P1) was taken just after induction, intubation, and installation of the central venous line. The next sample (P2) was taken in the postoperative unit 2 hours after de-clamping of the aorta. The third sample (P3) was collected 24 hours after operation. Blood was stored at 4°C, allowed to clot, and after centrifugation (10 minutes, 3,000 rpm) collected in 4 mL test tube Cryo (SARSTEDT AG & Co. KG, Nümbrecht, Germany). Samples of serum were stored at −30°C for later analysis. Protein S100ß was analyzed using the monoclonal two-site sandwich immunoluminometric assay Elecsys 100B, Cobas (Hoffmann-La Roche Ltd., Basel, Switzerland). The S-100 assay measures the ß-subunit of protein S-100 as defined by monoclonal antibodies, and the detection limit of the kit is 0.02 µg/L. The range of S100ß serum concentrations in 95% of healthy subjects is below 0.12 µg/L.

Statistical analysis
--------------------

The descriptive statistics were expressed as mean ± SD. For noncontinuous variables, the chi-squared test, Yates' chi-squared test, and Fisher's exact test were used, when necessary. For continuous variables with a normal distribution in the Kolmogorov--Smirnov test, the two-sample *t*-test was used. For the continuous variables without normal distribution, the Mann--Whitney *U* test for independent data samples and the Wilcoxon signed-rank test for correlated data samples were used.

Patients in the treatment and control groups were paired according to age (≤60 years and \<60 years) and sex. The first patient of each pair was chosen randomly using the Random Number Generator of Excel 97 (Microsoft Office; Microsoft Corporation, Redmond, WA, USA). The second patient from the opposite group was matched automatically. The results were considered significant when *P*\<0.05. The statistical analysis was performed using the licensed Statistica 12.0 software (Nr JPZP602C295824AR-V; StatSoft, Inc., Tulsa, OK, USA).

Results
=======

There were 49 patients in the treatment (T) group (23 women and 26 men, aged 41--77 years \[mean 61.7±9.35\]). In the control (C) group, there were 51 patients (22 women and 29 men, aged 45--79 years \[mean 64.2±8.5\]). The demographic and preoperative data are presented in [Table 1](#t1-cia-13-1837){ref-type="table"}. There were 60 mitral annuloplasty procedures using the Carpentier-Edwards Classic Annuloplasty Ring (Edwards Lifesciences, Irvine, CA, USA) or St Jude Medical™ Rigid Saddle Ring (St Jude Medical, St Paul, MN, USA) and 40 mitral valve replacements -- 19 with a standard bi-leaflet mechanical valve (ATS Medical, Minneapolis, MN, USA) and 21 with the Hancock II Tissue Valve (Medtronic, Minneapolis, MN, USA). Additionally, some other procedures were performed: 60 CABGs, 32 TVA, 29 radiofrequency monopolar ablations (MRFA), and three atrial septal defect (ASD) closures ([Table 2](#t2-cia-13-1837){ref-type="table"}). The postoperative data and complications are summarized in [Table 3](#t3-cia-13-1837){ref-type="table"}.

The results of S100ß level in blood plasma samples taken from patients in the treatment and control groups before the operation, 2 hours after de-clamping of the aorta, and 24 hours after the operation did not differ significantly between each other ([Table 4](#t4-cia-13-1837){ref-type="table"}). An analysis according to age in whole study group showed that in patients aged \<60 years, the serum level of S100ß 2 hours and 24 hours after the surgery was significantly higher compared to younger patients (1.358±0.634 µg/L vs 1.022±0.535 µg/L, *P*=0.008, and 0.279±0.218 vs 0.193±0.0908, *P*=0.005, respectively; [Table 5](#t5-cia-13-1837){ref-type="table"}). Similar results were observed in the study group (1.393±0.607 µg/L vs 0.847±0.45 µg/L, *P*\<0.001, and 0.322±0.303 µg/L vs 0.191±0.084 µg/L, *P*=0.016), but in the control group, there were no significant age-dependent differences ([Table 6](#t6-cia-13-1837){ref-type="table"}). Comparing younger patients in the treatment and control groups, 2 hours after the surgery, there were significant differences in S100ß level (0.847±0.45 µg/L vs 1.264±0.561 µg/L, *P*=0.015), but not at the beginning and after 24 hours. In the older patients in the treatment and control groups, the differences were not significant ([Table 7](#t7-cia-13-1837){ref-type="table"}).

It has also been observed that the additional procedure of TVA had an impact upon the increase in S100ß concentration in the whole patient cohort significant after 2 hours (*P*=0.049) and not significant after 24 hours from the operation ([Table 8](#t8-cia-13-1837){ref-type="table"}). The increase in S100ß concentration in the treatment group after 24 hours was statistically significant -- TVA (−) 0.21±0.09 vs TVA (+) 0.42±0.42, *P*=0.05 ([Table 8](#t8-cia-13-1837){ref-type="table"}). It has been shown that the serum S100ß concentration depends on age and a concomitant performance of TVA. In the older group with TVA, results were significantly higher than in the younger group (1.59±0.682 µg/L vs 1.055±0.561 µg/L, *P*=0.043, and 0.363±0.318 µg/L vs 0.189±0.074 µg/L, *P*\<0.001), both 2 hours and 24 hours after the surgery ([Table 9](#t9-cia-13-1837){ref-type="table"}). In the older group, there were significant differences in the S100ß level 2 hours and 24 hours after the procedure (1.59±0.682 µg/L vs 1.223±0.571 µg/L, *P*=0.048, and 0.363±0.318 µg/L vs 0.229±0.105 µg/L, *P*=0.036), when comparing the results of patients with and without TVA ([Table 10](#t10-cia-13-1837){ref-type="table"}). The only direct evidence that CO~2~ flooding could be effective was found when comparing the S100B results between younger patients in the study and control groups without TVA. In the second measure, 2 hours after surgery, we also found significant differences (0.845±0.465 µg/L vs 0.845±0.465 µg/L, *P*=0.028).

Discussion
==========

In our study, the mean increase in the S100ß concentration was 13% lower in the group with CO~2~ protection than in the control group (0.988 µg/L vs 1.125 µg/L), but the differences were statistically insignificant. We observed significant differences in S100ß concentrations depending on the age of the patients. In the group of patients older than 60 years, the S100ß concentrations were significantly higher both 2 hours and 24 hours after the surgery. Among patients aged ≤60 years, significantly lower values of S100ß concentrations were found between the treatment and control groups 2 hours after the surgery and in the subgroup without additional procedures, namely, mitral valve annuloplasty. These results suggest the potential impact of CO~2~ flooding on S100ß concentrations but unfortunately not found in other analyses.

We have also demonstrated that performing an additional TVA procedure has a significant impact on the increase in S100ß concentrations in postoperative studies. This might have been caused by increased suction from the operating field since the application and tying of sutures to the tricuspid ring are performed after aortic cross-clamp release and the blood, which flows from the coronary sinus, requires intensive suction for a period of 10--20 minutes. This difference in the results of both groups (with and without TVA) made us realize the mistake of not including a proportional distribution of patients with TVA in our randomization assumptions. Due to the fact that the control group contained significantly more patients with TVA (treatment group: 11/49 vs control group: 21/51, *P*=0.045), which is associated with an increase in S100ß concentration, it has to be concluded that the differences between the two groups were even smaller in reality.

The important problem of finding a way to effectively replace air with CO~2~ in the operating field has been addressed by several clinical trials that established the principles of operating field insufflation offering an appropriate concentration of CO~2~ in the heart chambers in order to make sure that residual microbubbles of gas are largely filled with CO~2~.[@b19-cia-13-1837]--[@b21-cia-13-1837]

Yet, whether the method is legitimate or not remains an open question. Microbubbles of air reach cerebral circulation during virtually all of cardiac surgery procedures. Although their number increases considerably when opening the chambers of the heart, they do not cause measurable symptoms and it is impossible to detect consequences of microembolism using typical neurological tests. Several studies demonstrated a correlation between small lesions in the brain detected on an magnetic resonance imaging (MRI) scan and neurological tests, but other studies have not confirmed these observations.[@b22-cia-13-1837]--[@b29-cia-13-1837]

Some authors were of the opinion that when comparing patients a few months after a cardiac procedure, neurological (behavioral) changes appear more often in patients after CABG than in patients after OPCAB, but these associations were denied by others.[@b30-cia-13-1837],[@b31-cia-13-1837] Martens et al[@b13-cia-13-1837] demonstrated that the number of air bubbles released to carotid arteries after weaning from CPB does not have to correlate with the occurrence of cognitive dysfunction.

Haggag et al[@b27-cia-13-1837] have shown, in a study performed on rats, that injection of air into the arterial system does not cause lesions typical for microembolism. Neville et al,[@b28-cia-13-1837] in a study comparing valve procedures with CABG, also did not find differences in the frequency of postoperative neurological dysfunction between the two groups, despite detecting much more air in carotid arteries on ultrasonography during valve procedures. In contrast, Herrmann et al[@b29-cia-13-1837] have shown that operations involving opening of the heart chambers result in a higher percentage of neurological dysfunctions and a higher increase in brain damage biomarkers in comparison to CABG. Martens et al[@b30-cia-13-1837] examined the influence of delivering air and CO~2~ to the carotid arteries of pigs on the occurrence of lesions on an MRI scan and concluded that air caused extensive cerebral infarction while CO~2~ did not cause any lesions that would be detectable with MRI. However, it must be underlined that a large amount of air reaching cerebral arteries during a cardiac surgery may only be a result of technical error.

Our study is not without limitations. First, other concomitant procedures (TVP or CABG) may influence the CPB times and the levels of S100ß. Second, the study reports laboratory findings, without a clinical postoperative perspective. The postoperative dementia screening (Mini Mental State Examination \[MMSE\]) or a detailed neurocognitive examination during the follow-up period would provide an important insight into the effect of CO~2~ flooding on neurological outcome. Third, the number of patients included in the study is relatively small and further research might be required to eliminate sample size effect. Fourth, although elevated serum S100B levels after cardiac operations with CPB are sensitive and specific for ischemic stroke, its appearance in surgical patients without neurological injury and its potential release from extracranial sources (ie, adipocytes, chondrocytes, and melanocytes) make its use as a postoperative biomarker of neurological insult debatable.[@b4-cia-13-1837],[@b32-cia-13-1837]--[@b36-cia-13-1837] Moreover, the use of

CO~2~ atmosphere has been debatable.[@b37-cia-13-1837],[@b38-cia-13-1837] Nevertheless, we believe that notwithstanding shortages in our randomization assumptions, our study still offers important insights that are relevant to surgical practice.

Conclusion
==========

The mean increase in S100ß concentration was lower in the group with CO~2~ protection than in the control group. Both age and an addition of TVA significantly influenced the level of S100ß concentration in the tests performed 2 hours after aortic clamp release.
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###### 

Demographic data

  Preoperative data                       Treatment group, n=49   Control group, n=51   *P*-value
  --------------------------------------- ----------------------- --------------------- -----------------------------------------------
  Sex                                                                                   
   Male, n (%)                            26 (53.1)               29 (56.9)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
   Female, n (%)                          23 (46.9)               22 (43.1)             
  Age (years)                                                                           
   Total, mean ± SD                       61.7±9.35               64.20±8.55            NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}
   Male, mean ± SD                        61.15±9.57              63.38±9.02            NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}
   Female, mean ± SD                      62.35±9.27              65.27±7.96            NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}
  EuroScore logistics (%), mean ± SD      6.42±6.15               7.11±5.59             NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}
  Ejection fraction (%), mean ± SD        47.2±14.25              48.9±13.61            NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}
  Distribution of NYHA class, mean ± SD   2.71±0.68               2.53±0.86             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Coronary artery disease, n (%)          31 (63.3)               39 (76.5)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Myocardial infarction, n (%)            14 (28.5)               15 (29.4)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Diabetes, n (%)                         13 (26.5)               16 (31.4)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Hypertension, n (%)                     28 (57.1)               28 (54.9)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Paroxysmal AF, n (%)                    12 (24.5)               9 (17.6)              NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Chronic AF, n (%)                       12 (24.5)               18 (35.3)             NS[a](#tfn1-cia-13-1837){ref-type="table-fn"}
  Chronic kidney disease, n (%)           2 (4.1)                 8 (15.7)              NS[c](#tfn3-cia-13-1837){ref-type="table-fn"}
  Creatinine (µmol/L), mean ± SD          83.1±28.3               88.4±25.6             NS[b](#tfn2-cia-13-1837){ref-type="table-fn"}

**Notes:**

Chi-squared test.

Mann--Whitney *U* test.

Fisher's exact test.

**Abbreviations:** AF, atrial fibrillation; NYHA, New York Heart Association; NS, not significant.

###### 

Procedures and intraoperative data

  Intraoperative data                            Treatment group, n=49   Control group, n=51   *P*-value
  ---------------------------------------------- ----------------------- --------------------- ---------------------------------------------------------------------------------------------
  Mitral annuloplasty, n (%)                     33 (67.3)               27 (52.9)             NS[a](#tfn5-cia-13-1837){ref-type="table-fn"}
  Mitral valve replacement, n (%)                16 (32.6)               24 (47.1)             NS[a](#tfn5-cia-13-1837){ref-type="table-fn"}
  Tricuspid valve annuloplasty, n (%)            11 (22.4)               21 (41.2)             0.04[a](#tfn5-cia-13-1837){ref-type="table-fn"},[b](#tfn6-cia-13-1837){ref-type="table-fn"}
  Radiofrequency ablation, n (%)                 15 (30.6)               14 (27.4)             NS[a](#tfn5-cia-13-1837){ref-type="table-fn"}
  ASD II closure, n (%)                          1 (2.04)                2 (3.92)              NS[c](#tfn7-cia-13-1837){ref-type="table-fn"}
  CABG, n (%)                                    29 (59.1)               31 (60.7)             NS[a](#tfn5-cia-13-1837){ref-type="table-fn"}
  Number of anastomoses, mean                    2.65                    2.71                  NS[d](#tfn8-cia-13-1837){ref-type="table-fn"}
  Aortic cross-clamp time (minutes), mean ± SD   51.18±11.92             54.90±11.06           NS[e](#tfn9-cia-13-1837){ref-type="table-fn"}
  CPB time (minutes), mean ± SD                  72.18±17.70             78.57±16.42           NS[e](#tfn9-cia-13-1837){ref-type="table-fn"}

**Notes:**

Chi-squared test.

Significant at *P*\<0.05.

Fisher's exact test.

Mann--Whitney *U* test.

Two-sample *t*-test.

**Abbreviations:** ASD, atrial septal defect; CABG, coronary artery by-pass grafting; CPB, cardiopulmonary bypass; NS, not significant.

###### 

Complications and postoperative data

  Postoperative data                                     Treatment group, n=49   Control group, n=51   *P*-value
  ------------------------------------------------------ ----------------------- --------------------- ------------------------------------------------
  CKMB (U/dL) 6 hours after operation, mean ± SD         55.59±23.02             56.31±21.96           NS[a](#tfn11-cia-13-1837){ref-type="table-fn"}
  CKMB (U/dL) 12 hours after operation, mean ± SD        59.59±31.50             56.74±34.73           NS[a](#tfn11-cia-13-1837){ref-type="table-fn"}
  CKMB (U/dL) 18 hours after operation, mean ± SD        56.31±20.91             54.66±23.64           NS[a](#tfn11-cia-13-1837){ref-type="table-fn"}
  Postoperative atrial fibrillation, n (%)               11 (22.45)              5 (9.80)              NS[b](#tfn12-cia-13-1837){ref-type="table-fn"}
  Acute kidney injury, n (%)                             4 (8.16)                2 (3.92)              NS[c](#tfn13-cia-13-1837){ref-type="table-fn"}
  AKI requiring hemofiltration, n (%)                    2 (4.08)                0                     NS[c](#tfn13-cia-13-1837){ref-type="table-fn"}
  Chronic kidney disease requiring hemodialysis, n (%)   2 (4.08)                4 (7.84)              NS[c](#tfn13-cia-13-1837){ref-type="table-fn"}
  Cerebrovascular incident, n (%)                        1 (2.04)                3 (5.88)              NS[c](#tfn13-cia-13-1837){ref-type="table-fn"}
  Maximum creatinine level, mean ± SD                    1.32±0.73               1.35±0.95             NS[b](#tfn12-cia-13-1837){ref-type="table-fn"}
  Death, n (%)                                           3 (6.12)                1 (1.96)              NS[c](#tfn13-cia-13-1837){ref-type="table-fn"}
  Postoperative ejection fraction (%), mean ± SD         45.10±10.97             45.98±11.58           NS[b](#tfn12-cia-13-1837){ref-type="table-fn"}
  Hospital stay (days), mean ± SD                        10.14±4.40              10.49±7.68            NS[b](#tfn12-cia-13-1837){ref-type="table-fn"}

**Notes:**

Yates' chi-squared test.

Mann--Whitney *U* test.

Fisher's exact test.

**Abbreviations:** AKI, acute kidney injury; CKMB, creatinine kinase-MB; NS, not significant.

###### 

The S100ß levels at predefined study times

  Results                                                  Treatment group, n=49   Control group, n=51   *P*-value[a](#tfn15-cia-13-1837){ref-type="table-fn"}
  -------------------------------------------------------- ----------------------- --------------------- -------------------------------------------------------
  Initial level of S100ß (µg/L), mean ± SD                 0.13±0.08               0.18±0.19             NS
  S100ß level 2 hours after declamping (µg/L), mean ± SD   1.12±0.59               1.31±0.62             NS
  S100ß level 24 hours after operation (µg/L), mean ± SD   0.26±0.23               0.23±0.12             NS

**Note:**

Mann--Whitney *U* test.

**Abbreviation:** NS, not significant.

###### 

The differences of S100ß serum concentration according to age of the patients in the whole group of patients

  Results                                                  Age ≤60 years, n=42   Age \<60 years, n=58   *P*-value[a](#tfn17-cia-13-1837){ref-type="table-fn"}
  -------------------------------------------------------- --------------------- ---------------------- -------------------------------------------------------
  Initial level of S100ß (µg/L), mean ± SD                 0.142±0.151           0.165±0.155            NS
  S100ß level 2 hours after declamping (µg/L), mean ± SD   1.022±0.535           1.358±0.634            0.008
  S100ß level 24 hours after operation (µg/L), mean ± SD   0.193±0.0908          0.279±0.218            0.005

**Note:**

Mann--Whitney *U* test.

**Abbreviation:** NS, not significant.

###### 

The differences of S100ß serum concentration according to age of the patients in the study and control groups

  Results, mean ± SD                            Treatment group   *P*-value[a](#tfn19-cia-13-1837){ref-type="table-fn"}   Control group   *P*-value[a](#tfn19-cia-13-1837){ref-type="table-fn"}                 
  --------------------------------------------- ----------------- ------------------------------------------------------- --------------- ------------------------------------------------------- ------------- ----
  Initial level of S100ß (µg/L)                 0.115±0.0937      0.138±0.0738                                            NS              0.179±0.204                                             0.185±0.193   NS
  S100ß level 2 hours after declamping (µg/L)   0.847±0.45        1.393±0.607                                             \<0.001         1.264±0.561                                             1.332±0.662   NS
  S100ß level 24 hours after operation (µg/L)   0.191±0.084       0.322±0.303                                             0.016           0.197±0.102                                             0.247±0.121   NS

**Note:**

Mann--Whitney *U* test.

**Abbreviation:** NS, not significant.

###### 

The differences of S100ß serum concentration between the study and control groups according to the age of patients

  Results, mean ± SD                            Age ≤60 years   *P*-value[a](#tfn21-cia-13-1837){ref-type="table-fn"}   Age \<60 years   *P*-value[a](#tfn21-cia-13-1837){ref-type="table-fn"}                 
  --------------------------------------------- --------------- ------------------------------------------------------- ---------------- ------------------------------------------------------- ------------- ----
  Initial level of S100ß (µg/L)                 0.115±0.0937    0.179±0.204                                             NS               0.138±0.0738                                            0.185±0.193   NS
  S100ß level 2 hours after declamping (µg/L)   0.847±0.45      1.264±0.561                                             0.015            1.393±0.607                                             1.332±0.662   NS
  S100ß level 24 hours after operation (µg/L)   0.191±0.084     0.197±0.102                                             NS               0.322±0.303                                             0.247±0.121   NS

**Note:**

Mann--Whitney *U* test.

**Abbreviation:** NS, not significant.

###### 

Results in relation to TVA procedures in the whole group and in the treatment and control groups

                                TVA (−), mean ± SD   TVA (+), mean ± SD   *P*-value
  ----------------------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------
  Whole group                                                             
   Initial S100ß level          0.16±0.16            0.153±0.13           NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
   S100ß level after 2 hours    1.12±0.56            1.41±0.68            0.049[a](#tfn23-cia-13-1837){ref-type="table-fn"},[b](#tfn24-cia-13-1837){ref-type="table-fn"}
   S100ß level after 24 hours   0.21±0.1             0.30±0.27            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
  Treatment group                                                         
   Initial S100ß level          0.13±0.09            0.12±0.05            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
   S100ß level after 2 hours    1.06±0.56            1.31±0.70            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
   S100ß level after 24 hours   0.21±0.09            0.42±0.42            0.05[a](#tfn23-cia-13-1837){ref-type="table-fn"},[b](#tfn24-cia-13-1837){ref-type="table-fn"}
  Control group                                                           
   Initial S100ß level          0.19±0.22            0.17±0.15            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
   S100ß level after 2 hours    1.20±0.56            1.46±0.69            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}
   S100ß level after 24 hours   0.22±0.11            0.24±0.12            NS[a](#tfn23-cia-13-1837){ref-type="table-fn"}

**Notes:**

Mann--Whitney *U* test.

Significant at *P*\<0.05.

**Abbreviations:** NS, not significant; TVA, tricuspid valve annuloplasty.

###### 

The differences of S100ß serum concentration between the group with or without additional TVA procedure according to age of the patients

  Results                                       TVA (+), mean ± SD   *P*-value[a](#tfn26-cia-13-1837){ref-type="table-fn"}   TVA (−), mean ± SD   *P*-value[a](#tfn26-cia-13-1837){ref-type="table-fn"}                 
  --------------------------------------------- -------------------- ------------------------------------------------------- -------------------- ------------------------------------------------------- ------------- ----
  Initial level of S100ß (µg/L)                 0.109±0.062          0.176±0.15                                              NS                   0.153±0.171                                             0.159±0.16    NS
  S100ß level 2 hours after declamping (µg/L)   1.055±0.561          1.59±0.682                                              0.043                1.01±0.534                                              1.223±0.571   NS
  S100ß level 24 hours after operation (µg/L)   0.189±0.074          0.363±0.318                                             \<0.001              0.195±0.097                                             0.229±0.105   NS

**Note:**

Mann--Whitney *U* test.

**Abbreviations:** NS, not significant; TVA, tricuspid valve annuloplasty.

###### 

The differences of S100ß serum concentration according to age of the patients between the group with or without additional TVA procedure according to age of the patients

  Results                                       Age ≤60 years, mean ± SD   *P*-value[a](#tfn28-cia-13-1837){ref-type="table-fn"}   Age \<60 years, mean ± SD   *P*-value[a](#tfn28-cia-13-1837){ref-type="table-fn"}                 
  --------------------------------------------- -------------------------- ------------------------------------------------------- --------------------------- ------------------------------------------------------- ------------- -------
  Initial level of S100ß (µg/L)                 0.109±0.062                0.153±0.171                                             NS                          0.176±0.15                                              0.159±0.16    NS
  S100ß level 2 hours after declamping (µg/L)   1.055±0.561                1.01±0.534                                              NS                          1.59±0.682                                              1.223±0.571   0.048
  S100ß level 24 hours after operation (µg/L)   0.189±0.074                0.195±0.097                                             NS                          0.363±0.318                                             0.229±0.105   0.036

**Note:**

Mann--Whitney *U* test.

**Abbreviations:** NS, not significant; TVA, tricuspid valve annuloplasty.
